<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501928</url>
  </required_header>
  <id_info>
    <org_study_id>A0221109</org_study_id>
    <nct_id>NCT02501928</nct_id>
  </id_info>
  <brief_title>Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.</brief_title>
  <official_title>LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of fesoterodine&#xD;
      following once daily long-term treatment in Japanese pediatric neurogenic detrusor&#xD;
      overactivity (NDO) subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multi-center, open-label long-term extension study in Japanese NDO&#xD;
      subjects who participated and completed in the precedent Study A0221047 which is a 24 weeks,&#xD;
      randomized, open label study, to investigate the safety and tolerability of fesoterodine.&#xD;
&#xD;
      This study consists of a 28-week open-label treatment period followed by a 4-week follow-up.&#xD;
      In addition, subjects in the oxybutynin arm of the precedent Study A0221047 will continue the&#xD;
      fesoterodine treatment until Week 40 visit in this study, in order to obtain fesoterodine 1&#xD;
      year treatment data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2015</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109</measure>
    <time_frame>Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. TEAEs were summarized for each cohort (Cohort 1 and Cohort 2, irrespective of treatment received), each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Acuity at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>Visual acuity (VA) was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Acuity at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Acuity at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Accommodation at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Accommodation at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Accommodation at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Time to Completion: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of Study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10- or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Blood Pressure) at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Blood Pressure) at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Blood Pressure) at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Pulse Rate) at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Pulse Rate) at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign (Pulse Rate) at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Event Urinary Tract Infections (UTI): Merged Data of Studies A0221047 and A0221109</measure>
    <time_frame>Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)</time_frame>
    <description>UTI data were summarized for each cohort, each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>A0221109: Baseline to 28 weeks</time_frame>
    <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN); platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN); leukocytes &lt;0.6*LLN&gt;1.5*ULN; lymphocytes, neutrophils &lt;0.8*LLN &gt;1.2*UL; basophils, eosinophils, monocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct bilirubin &gt;1.5*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase &gt;3.0*ULN; protein, albumin &lt;0.8*LLN &gt;1.2*ULN; blood urea nitrogen, creatinine &gt;1.3*ULN; urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN; potassium, chloride, bicarbonate &lt;0.9*LLN&gt;1.1*ULN; glucose &lt;0.6*LLN&gt;1.5*ULN; creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, glucose, ketones, protein, hemoglobin, nitrite, leukocyte esterase &gt;=1; erythrocytes, leukocytes &gt;=20; epithelial cells &gt;=6, bacteria &gt;20, hyaline casts &gt;1. Data for this outcome was planned to be analysed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Post-Void Residual (PVR) Volume at Week 12: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 12</time_frame>
    <description>Post-void residual volume was assessed by an ultrasound. PVR volume was assessed only in participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Post-Void Residual (PVR) Volume at Week 28: Study A0221109</measure>
    <time_frame>A0221109: Baseline, Week 28</time_frame>
    <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Post-Void Residual (PVR) Volume at Final Visit: Study A0221109</measure>
    <time_frame>A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Maximum cystometric bladder capacity was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O). Maximum cystometric bladder capacity was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Detrusor pressure (cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing. Detrusor pressure was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Presence of Involuntary Detrusor Contraction (IDC) at Baseline and Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Participants with presence of IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Bladder volume at first IDC was measured using urodynamic testing. Bladder volume at first IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bladder Compliance at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated). Bladder Compliance was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions or Catheterizations Combined Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean number of micturitions and catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour (hr) period. This outcome measure was only calculated for participants with &gt;0 micturitions or catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for sensate participants with &gt;0 urgency episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Micturition at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per micturition. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per catherization. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</measure>
    <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
    <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume &gt;0. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Urinary Bladder, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 4 mg</intervention_name>
    <description>Fesoterodine 4 mg tablet once daily for 28 or 40 weeks</description>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 8 mg</intervention_name>
    <description>Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks</description>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 2 mg</intervention_name>
    <description>Fesoterodine BIC 2 mg tablet once daily for 28 weeks</description>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 4 mg</intervention_name>
    <description>Fesoterodine BIC 4 mg tablet once daily for 28 weeks</description>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who completed 24 week treatment and all visit procedures in the precedent Study&#xD;
        A0221047&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study&#xD;
             A0221047&#xD;
&#xD;
          -  Concomitant medications which may increase the risk to subjects or confound study&#xD;
             results&#xD;
&#xD;
          -  Other medical conditions which may increase the risk to subjects or confound study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Children's Hospital</name>
      <address>
        <city>Midori-ku Chiba-shi</city>
        <state>Chiba</state>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital</name>
      <address>
        <city>Izumi-shi</city>
        <state>Osaka</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Aoi-ku Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga-gun</city>
        <state>Tochigi</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221109&amp;StudyName=Long-term%20Extension%20Study%20To%20Evaluate%20The%20Safety%20Of%20Fesoterodine%20In%20Japanese%20Pediatric%20Subjects%20With%20Symptoms%20Of%20Detrusor%20Overactivity%20Associated%20With%20A%20Neurological%20Condition%20%28neurogenic%20Detrusor%20Overactivity%29%20Who%20Have%20Completed%2024%20Weeks%20Treatment%20In%20Study%20A0221047</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurogenic detrusor overactivity</keyword>
  <keyword>fesoterodine</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02501928/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02501928/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This (A0221109) was a long term extension (LTE) study only among Japanese participants who participated and completed the precedent study A0221047 (NCT01557244). Per plan, efficacy outcome measures and treatment-emergent adverse events were reported using merged data of studies A0221047 and A0221109.</recruitment_details>
      <pre_assignment_details>A0221047 had 2 cohorts. Cohort 1 had an active comparator phase and Cohort 2 had an efficacy phase followed by a safety extension phase for each cohort. Japanese participants from both cohorts, if consented continued in this LTE study and received the same treatment as in A0221047, per investigator judgment on safety and tolerance of participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fesoterodine 4 Milligram (mg) Tablet</title>
          <description>In precedent study A0221047, participants of cohort 1, with body weight greater than (&gt;) 25 kilogram (kg), received fesoterodine 4 mg prolonged release (PR) tablet once daily for 24 weeks (12 weeks in each active comparator and safety extension phase). Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 4 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="P2">
          <title>Fesoterodine 8 mg Tablet</title>
          <description>In precedent study A0221047, participants of cohort 1, with body weight &gt;25 kg, received fesoterodine 4 mg PR tablet once daily for 1 week and if well tolerated then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator phase and 12 weeks in safety extension phase. Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="P3">
          <title>Oxybutynin Then Fesoterodine 4 mg Tablet</title>
          <description>In precedent study A0221047, participants of cohort 1, with body weight &gt;25 kg, received oxybutynin tablet at daily dose per pediatric labelling in active comparator phase for 12 weeks and then fesoterodine 4 mg PR tablet in safety extension phase once daily for 12 weeks. Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 4 mg PR tablet orally once daily for another 40 weeks in this LTE study.</description>
        </group>
        <group group_id="P4">
          <title>Oxybutynin Then Fesoterodine 8 mg Tablet</title>
          <description>In precedent study A0221047, participants of cohort 1, with body weight &gt;25 kg, received oxybutynin tablet at daily dose per pediatric labelling in active comparator phase for 12 weeks and then fesoterodine 4 mg PR tablet once daily for 1 week and if tolerated well received 8 mg PR tablet once daily for 11 weeks in safety extension phase. Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 8 mg PR tablet orally once daily for another 40 weeks in this LTE study.</description>
        </group>
        <group group_id="P5">
          <title>Fesoterodine 2 mg Capsule</title>
          <description>In precedent study A0220147, participants of cohort 2, with body weight less than or equal to (&lt;=) 25 kg, received fesoterodine 2 mg beads-in-capsule (BIC) capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase). Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="P6">
          <title>Fesoterodine 4 mg Capsule</title>
          <description>In precedent study A0221047, participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase. Only Japanese participants, who consented to continue in this LTE study, were to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participant was assigned to this arm, in this LTE study.</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0">No participant was assigned to this arm, in this LTE study.</participants>
                <participants group_id="P4" count="0">No participant was assigned to this arm, in this LTE study.</participants>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal By Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics included only those reporting arms in which at least 1 participant was assigned. Analysis population included all enrolled participants who received at least 1 dose of study medication in this LTE study.</population>
      <group_list>
        <group group_id="B1">
          <title>Fesoterodine 8 mg Tablet</title>
          <description>Japanese participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet once daily for 1 week and if well tolerated then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator phase and for 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="B2">
          <title>Fesoterodine 2 mg Capsule</title>
          <description>Japanese participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study A0221047 and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="B3">
          <title>Fesoterodine 4 mg Capsule</title>
          <description>Japanese participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.50" spread="0.71"/>
                    <measurement group_id="B2" value="7.86" spread="1.68"/>
                    <measurement group_id="B3" value="7.33" spread="0.58"/>
                    <measurement group_id="B4" value="8.67" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. TEAEs were summarized for each cohort (Cohort 1 and Cohort 2, irrespective of treatment received), each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. TEAEs were summarized for each cohort (Cohort 1 and Cohort 2, irrespective of treatment received), each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Acuity at Week 12: Study A0221109</title>
        <description>Visual acuity (VA) was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity at Week 12: Study A0221109</title>
          <description>Visual acuity (VA) was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.376"/>
                    <measurement group_id="O2" value="0.04" spread="0.137"/>
                    <measurement group_id="O3" value="0.28" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.204"/>
                    <measurement group_id="O2" value="-0.03" spread="0.083"/>
                    <measurement group_id="O3" value="0.04" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.350"/>
                    <measurement group_id="O2" value="0.04" spread="0.183"/>
                    <measurement group_id="O3" value="0.63" spread="0.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.126"/>
                    <measurement group_id="O2" value="0.03" spread="0.116"/>
                    <measurement group_id="O3" value="0.07" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Acuity at Week 28: Study A0221109</title>
        <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity at Week 28: Study A0221109</title>
          <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                    <measurement group_id="O2" value="0.03" spread="0.118"/>
                    <measurement group_id="O3" value="0.02" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.681"/>
                    <measurement group_id="O2" value="0.05" spread="0.057"/>
                    <measurement group_id="O3" value="0.16" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Acuity at Final Visit: Study A0221109</title>
        <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity at Final Visit: Study A0221109</title>
          <description>VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                    <measurement group_id="O2" value="0.02" spread="0.108"/>
                    <measurement group_id="O3" value="0.02" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.681"/>
                    <measurement group_id="O2" value="0.04" spread="0.055"/>
                    <measurement group_id="O3" value="0.16" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Accommodation at Week 12: Study A0221109</title>
        <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Accommodation at Week 12: Study A0221109</title>
          <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" spread="8.014"/>
                    <measurement group_id="O2" value="8.62" spread="10.938"/>
                    <measurement group_id="O3" value="5.56" spread="4.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.593"/>
                    <measurement group_id="O2" value="5.86" spread="13.287"/>
                    <measurement group_id="O3" value="6.67" spread="10.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="13.199"/>
                    <measurement group_id="O2" value="9.86" spread="13.685"/>
                    <measurement group_id="O3" value="4.83" spread="6.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="2.593"/>
                    <measurement group_id="O2" value="3.24" spread="13.662"/>
                    <measurement group_id="O3" value="16.17" spread="23.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Accommodation at Week 28: Study A0221109</title>
        <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Accommodation at Week 28: Study A0221109</title>
          <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="7.307"/>
                    <measurement group_id="O2" value="0.78" spread="2.639"/>
                    <measurement group_id="O3" value="-0.11" spread="1.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="5.421"/>
                    <measurement group_id="O2" value="-0.39" spread="3.803"/>
                    <measurement group_id="O3" value="0.50" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Accommodation at Final Visit: Study A0221109</title>
        <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Accommodation at Final Visit: Study A0221109</title>
          <description>The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="7.307"/>
                    <measurement group_id="O2" value="4.38" spread="9.833"/>
                    <measurement group_id="O3" value="-0.11" spread="1.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="5.421"/>
                    <measurement group_id="O2" value="2.86" spread="9.263"/>
                    <measurement group_id="O3" value="0.50" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Study A0221109</title>
        <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Study A0221109</title>
          <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="52.6" spread="3.82"/>
                    <measurement group_id="O3" value="50.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggressive behavior: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="3.53"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="52.1" spread="3.34"/>
                    <measurement group_id="O3" value="50.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.7" spread="4.11"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="53.6" spread="3.55"/>
                    <measurement group_id="O3" value="53.3" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.1" spread="2.34"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="0.71"/>
                    <measurement group_id="O2" value="52.4" spread="3.60"/>
                    <measurement group_id="O3" value="53.3" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.3" spread="4.11"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="52.4" spread="2.70"/>
                    <measurement group_id="O3" value="54.3" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="3.65"/>
                    <measurement group_id="O3" value="0.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="2.12"/>
                    <measurement group_id="O2" value="53.4" spread="5.35"/>
                    <measurement group_id="O3" value="55.7" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.12"/>
                    <measurement group_id="O2" value="0.9" spread="1.46"/>
                    <measurement group_id="O3" value="-2.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="50.9" spread="1.46"/>
                    <measurement group_id="O3" value="53.0" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="1.70"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.00"/>
                    <measurement group_id="O2" value="53.4" spread="4.86"/>
                    <measurement group_id="O3" value="52.7" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.7" spread="4.54"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="4.24"/>
                    <measurement group_id="O2" value="47.6" spread="8.79"/>
                    <measurement group_id="O3" value="44.0" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.3" spread="6.07"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="4.24"/>
                    <measurement group_id="O2" value="49.0" spread="3.79"/>
                    <measurement group_id="O3" value="47.7" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.24"/>
                    <measurement group_id="O2" value="0.4" spread="5.00"/>
                    <measurement group_id="O3" value="-4.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="2.12"/>
                    <measurement group_id="O2" value="49.1" spread="3.67"/>
                    <measurement group_id="O3" value="46.7" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.24"/>
                    <measurement group_id="O2" value="-1.1" spread="2.12"/>
                    <measurement group_id="O3" value="0.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 28: Study A0221109</title>
        <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 28: Study A0221109</title>
          <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-2.2" spread="3.76"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.7" spread="4.13"/>
                    <measurement group_id="O3" value="0.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.0" spread="2.45"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-1.0" spread="2.97"/>
                    <measurement group_id="O3" value="1.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="1.63"/>
                    <measurement group_id="O3" value="1.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="1.2" spread="1.83"/>
                    <measurement group_id="O3" value="-2.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.2" spread="0.41"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-2.0" spread="7.04"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.24"/>
                    <measurement group_id="O2" value="-3.5" spread="5.92"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-2.5" spread="6.83"/>
                    <measurement group_id="O3" value="-2.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="3.54"/>
                    <measurement group_id="O2" value="-1.7" spread="2.94"/>
                    <measurement group_id="O3" value="1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Final Visit: Study A0221109</title>
        <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Final Visit: Study A0221109</title>
          <description>CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.9" spread="3.53"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.6" spread="3.78"/>
                    <measurement group_id="O3" value="0.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.9" spread="2.27"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-0.9" spread="2.73"/>
                    <measurement group_id="O3" value="1.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="1.50"/>
                    <measurement group_id="O3" value="1.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="1.0" spread="1.73"/>
                    <measurement group_id="O3" value="-2.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="0.38"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.7" spread="6.47"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.24"/>
                    <measurement group_id="O2" value="-3.0" spread="5.57"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-2.1" spread="6.31"/>
                    <measurement group_id="O3" value="-2.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="3.54"/>
                    <measurement group_id="O2" value="-1.4" spread="2.76"/>
                    <measurement group_id="O3" value="1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 12: Study A0221109</title>
        <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 12: Study A0221109</title>
          <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="3.4" spread="3.05"/>
                    <measurement group_id="O3" value="2.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggressive behavior: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="2.97"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="1.9" spread="1.57"/>
                    <measurement group_id="O3" value="1.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="1.60"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="3.6" spread="2.64"/>
                    <measurement group_id="O3" value="3.0" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.6" spread="1.27"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="1.3" spread="1.50"/>
                    <measurement group_id="O3" value="1.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="1.21"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="1.6" spread="1.27"/>
                    <measurement group_id="O3" value="2.3" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="1.63"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="1.0" spread="1.53"/>
                    <measurement group_id="O3" value="1.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="0.3" spread="0.49"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.6" spread="0.79"/>
                    <measurement group_id="O3" value="1.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="0.69"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.9" spread="1.21"/>
                    <measurement group_id="O3" value="0.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.4" spread="1.13"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="4.7" spread="4.27"/>
                    <measurement group_id="O3" value="3.3" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.3" spread="3.59"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="3.7" spread="1.38"/>
                    <measurement group_id="O3" value="3.7" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="0.1" spread="2.19"/>
                    <measurement group_id="O3" value="-1.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.71"/>
                    <measurement group_id="O2" value="19.1" spread="5.79"/>
                    <measurement group_id="O3" value="18.0" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.41"/>
                    <measurement group_id="O2" value="-1.3" spread="4.07"/>
                    <measurement group_id="O3" value="-0.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 28: Study A0221109</title>
        <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 28: Study A0221109</title>
          <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.8" spread="3.06"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.3" spread="1.37"/>
                    <measurement group_id="O3" value="0.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="1.22"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-0.2" spread="0.98"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.2" spread="0.98"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="0.52"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.2" spread="0.41"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="1.76"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-2.0" spread="3.58"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="2.88"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-2.7" spread="4.63"/>
                    <measurement group_id="O3" value="0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Final Visit: Study A0221109</title>
        <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Final Visit: Study A0221109</title>
          <description>CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-1.6" spread="2.88"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.3" spread="1.25"/>
                    <measurement group_id="O3" value="0.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.4" spread="1.13"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-0.1" spread="0.90"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.1" spread="0.90"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.3" spread="0.49"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.1" spread="0.38"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.4" spread="1.62"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-1.7" spread="3.35"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.4" spread="2.64"/>
                    <measurement group_id="O3" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="-2.3" spread="4.35"/>
                    <measurement group_id="O3" value="0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="43.0" spread="23.44"/>
                    <measurement group_id="O3" value="39.3" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8" spread="6.72"/>
                    <measurement group_id="O3" value="-0.3" spread="15.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="33.4" spread="10.74"/>
                    <measurement group_id="O3" value="52.0" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.2" spread="19.93"/>
                    <measurement group_id="O3" value="-1.3" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.5" spread="2.38"/>
                    <measurement group_id="O3" value="3.7" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.3" spread="7.37"/>
                    <measurement group_id="O3" value="-7.7" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8" spread="8.53"/>
                    <measurement group_id="O3" value="3.7" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.4" spread="7.60"/>
                    <measurement group_id="O3" value="-7.7" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="6.36"/>
                    <measurement group_id="O2" value="107.5" spread="75.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.83"/>
                    <measurement group_id="O2" value="-11.5" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" spread="6.36"/>
                    <measurement group_id="O2" value="145.5" spread="132.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="4.95"/>
                    <measurement group_id="O2" value="-2.0" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="7.07"/>
                    <measurement group_id="O2" value="-14.0" spread="24.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.83"/>
                    <measurement group_id="O2" value="-35.0" spread="48.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Time to Completion: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Time to Completion: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="7.07"/>
                    <measurement group_id="O2" value="-14.0" spread="24.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.83"/>
                    <measurement group_id="O2" value="-35.0" spread="48.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2" spread="0.45"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2" spread="0.45"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.6" spread="1.34"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.3" spread="0.96"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of Study A0221109 only.</description>
        <time_frame>A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of Study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2" spread="0.84"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10- or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10- or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.0" spread="0.00"/>
                    <measurement group_id="O3" value="10.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.0" spread="0.00"/>
                    <measurement group_id="O3" value="10.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arm &quot;Fesoterodine 8 mg Tablet&quot; was below age of 9 years.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="0.00"/>
                    <measurement group_id="O2" value="25.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="0.00"/>
                    <measurement group_id="O2" value="25.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in the reporting arm &quot;Fesoterodine 4 mg Capsule&quot; was of age 9 years and above.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Blood Pressure) at Week 12: Study A0221109</title>
        <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Blood Pressure) at Week 12: Study A0221109</title>
          <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="4.24"/>
                    <measurement group_id="O2" value="2.1" spread="9.65"/>
                    <measurement group_id="O3" value="5.0" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="4.95"/>
                    <measurement group_id="O2" value="-0.9" spread="8.90"/>
                    <measurement group_id="O3" value="6.3" spread="15.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Blood Pressure) at Week 28: Study A0221109</title>
        <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Blood Pressure) at Week 28: Study A0221109</title>
          <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure.</population>
          <units>millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="16.26"/>
                    <measurement group_id="O2" value="5.7" spread="11.18"/>
                    <measurement group_id="O3" value="9.7" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="4.24"/>
                    <measurement group_id="O2" value="5.3" spread="9.03"/>
                    <measurement group_id="O3" value="10.7" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Blood Pressure) at Final Visit: Study A0221109</title>
        <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Blood Pressure) at Final Visit: Study A0221109</title>
          <description>Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="16.26"/>
                    <measurement group_id="O2" value="5.1" spread="10.30"/>
                    <measurement group_id="O3" value="9.7" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="4.24"/>
                    <measurement group_id="O2" value="4.6" spread="8.48"/>
                    <measurement group_id="O3" value="10.7" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Pulse Rate) at Week 12: Study A0221109</title>
        <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Pulse Rate) at Week 12: Study A0221109</title>
          <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="18.38"/>
                    <measurement group_id="O2" value="2.4" spread="12.53"/>
                    <measurement group_id="O3" value="-8.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Pulse Rate) at Week 28: Study A0221109</title>
        <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Pulse Rate) at Week 28: Study A0221109</title>
          <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. Here, &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="6.36"/>
                    <measurement group_id="O2" value="-2.7" spread="8.82"/>
                    <measurement group_id="O3" value="-3.7" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign (Pulse Rate) at Final Visit: Study A0221109</title>
        <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign (Pulse Rate) at Final Visit: Study A0221109</title>
          <description>Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="6.36"/>
                    <measurement group_id="O2" value="-1.4" spread="8.70"/>
                    <measurement group_id="O3" value="-3.7" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Event Urinary Tract Infections (UTI): Merged Data of Studies A0221047 and A0221109</title>
        <description>UTI data were summarized for each cohort, each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Event Urinary Tract Infections (UTI): Merged Data of Studies A0221047 and A0221109</title>
          <description>UTI data were summarized for each cohort, each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Abnormalities</title>
        <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN); platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN); leukocytes &lt;0.6*LLN&gt;1.5*ULN; lymphocytes, neutrophils &lt;0.8*LLN &gt;1.2*UL; basophils, eosinophils, monocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct bilirubin &gt;1.5*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase &gt;3.0*ULN; protein, albumin &lt;0.8*LLN &gt;1.2*ULN; blood urea nitrogen, creatinine &gt;1.3*ULN; urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN; potassium, chloride, bicarbonate &lt;0.9*LLN&gt;1.1*ULN; glucose &lt;0.6*LLN&gt;1.5*ULN; creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, glucose, ketones, protein, hemoglobin, nitrite, leukocyte esterase &gt;=1; erythrocytes, leukocytes &gt;=20; epithelial cells &gt;=6, bacteria &gt;20, hyaline casts &gt;1. Data for this outcome was planned to be analysed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline to 28 weeks</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Laboratory Abnormalities</title>
          <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN); platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN); leukocytes &lt;0.6*LLN&gt;1.5*ULN; lymphocytes, neutrophils &lt;0.8*LLN &gt;1.2*UL; basophils, eosinophils, monocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct bilirubin &gt;1.5*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase &gt;3.0*ULN; protein, albumin &lt;0.8*LLN &gt;1.2*ULN; blood urea nitrogen, creatinine &gt;1.3*ULN; urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN; potassium, chloride, bicarbonate &lt;0.9*LLN&gt;1.1*ULN; glucose &lt;0.6*LLN&gt;1.5*ULN; creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, glucose, ketones, protein, hemoglobin, nitrite, leukocyte esterase &gt;=1; erythrocytes, leukocytes &gt;=20; epithelial cells &gt;=6, bacteria &gt;20, hyaline casts &gt;1. Data for this outcome was planned to be analysed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in Study A0221109.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Post-Void Residual (PVR) Volume at Week 12: Study A0221109</title>
        <description>Post-void residual volume was assessed by an ultrasound. PVR volume was assessed only in participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 12</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual (PVR) Volume at Week 12: Study A0221109</title>
          <description>Post-void residual volume was assessed by an ultrasound. PVR volume was assessed only in participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Post-Void Residual (PVR) Volume at Week 28: Study A0221109</title>
        <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, Week 28</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual (PVR) Volume at Week 28: Study A0221109</title>
          <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Post-Void Residual (PVR) Volume at Final Visit: Study A0221109</title>
        <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
        <time_frame>A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual (PVR) Volume at Final Visit: Study A0221109</title>
          <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.</description>
          <population>Safety analysis set included all participants who were enrolled and received at least one dose of study medication in study A0221109. All participants performed clean intermittent catheterization, hence were not eligible for post-void residual volume assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>Maximum cystometric bladder capacity was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O). Maximum cystometric bladder capacity was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>Full analysis set (FAS) included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>Maximum cystometric bladder capacity was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O). Maximum cystometric bladder capacity was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>Full analysis set (FAS) included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.0" spread="28.28"/>
                    <measurement group_id="O2" value="135.5" spread="45.21"/>
                    <measurement group_id="O3" value="181.0" spread="28.28"/>
                    <measurement group_id="O4" value="149.7" spread="38.49"/>
                    <measurement group_id="O5" value="102.3" spread="48.95"/>
                    <measurement group_id="O6" value="143.1" spread="45.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.0" spread="56.57"/>
                    <measurement group_id="O2" value="42.9" spread="31.01"/>
                    <measurement group_id="O3" value="153.0" spread="56.57"/>
                    <measurement group_id="O4" value="37.6" spread="28.83"/>
                    <measurement group_id="O5" value="55.3" spread="38.76"/>
                    <measurement group_id="O6" value="61.3" spread="53.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.5" spread="30.41"/>
                    <measurement group_id="O2" value="37.9" spread="53.99"/>
                    <measurement group_id="O3" value="121.5" spread="30.41"/>
                    <measurement group_id="O4" value="32.8" spread="52.42"/>
                    <measurement group_id="O5" value="48.0" spread="67.55"/>
                    <measurement group_id="O6" value="53.1" spread="59.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.5" spread="30.41"/>
                    <measurement group_id="O2" value="37.9" spread="53.99"/>
                    <measurement group_id="O3" value="121.5" spread="30.41"/>
                    <measurement group_id="O4" value="32.8" spread="52.42"/>
                    <measurement group_id="O5" value="48.0" spread="67.55"/>
                    <measurement group_id="O6" value="53.1" spread="59.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>Detrusor pressure (cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing. Detrusor pressure was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>Detrusor pressure (cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing. Detrusor pressure was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="8.49"/>
                    <measurement group_id="O2" value="40.2" spread="31.34"/>
                    <measurement group_id="O3" value="29.0" spread="8.49"/>
                    <measurement group_id="O4" value="32.4" spread="11.57"/>
                    <measurement group_id="O5" value="58.3" spread="57.55"/>
                    <measurement group_id="O6" value="38.3" spread="28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="0.71"/>
                    <measurement group_id="O2" value="-13.7" spread="24.90"/>
                    <measurement group_id="O3" value="-5.5" spread="0.71"/>
                    <measurement group_id="O4" value="-6.0" spread="7.85"/>
                    <measurement group_id="O5" value="-31.7" spread="43.73"/>
                    <measurement group_id="O6" value="-12.3" spread="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="0.00"/>
                    <measurement group_id="O2" value="-4.3" spread="23.93"/>
                    <measurement group_id="O3" value="-7.0" spread="0.00"/>
                    <measurement group_id="O4" value="-2.8" spread="2.86"/>
                    <measurement group_id="O5" value="-7.3" spread="47.44"/>
                    <measurement group_id="O6" value="-4.8" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="0.00"/>
                    <measurement group_id="O2" value="-4.3" spread="23.93"/>
                    <measurement group_id="O3" value="-7.0" spread="0.00"/>
                    <measurement group_id="O4" value="-2.8" spread="2.86"/>
                    <measurement group_id="O5" value="-7.3" spread="47.44"/>
                    <measurement group_id="O6" value="-4.8" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Presence of Involuntary Detrusor Contraction (IDC) at Baseline and Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>Participants with presence of IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Presence of Involuntary Detrusor Contraction (IDC) at Baseline and Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>Participants with presence of IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>Bladder volume at first IDC was measured using urodynamic testing. Bladder volume at first IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit. Overall number of participants analyzed=participants evaluable for this outcome measure. Number Analyzed=participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>Bladder volume at first IDC was measured using urodynamic testing. Bladder volume at first IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit. Overall number of participants analyzed=participants evaluable for this outcome measure. Number Analyzed=participants evaluable for this outcome measure for specified rows.</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.0"/>
                    <measurement group_id="O2" value="48.8" spread="31.65"/>
                    <measurement group_id="O3" value="175.0"/>
                    <measurement group_id="O4" value="48.1" spread="36.57"/>
                    <measurement group_id="O5" value="50.3" spread="22.14"/>
                    <measurement group_id="O6" value="60.3" spread="48.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="95.0" spread="53.88"/>
                    <measurement group_id="O4" value="113.8" spread="68.55"/>
                    <measurement group_id="O5" value="70.0" spread="4.58"/>
                    <measurement group_id="O6" value="95.0" spread="53.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50.4" spread="36.38"/>
                    <measurement group_id="O4" value="38.6" spread="24.46"/>
                    <measurement group_id="O5" value="70.0" spread="50.11"/>
                    <measurement group_id="O6" value="50.4" spread="36.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50.4" spread="36.38"/>
                    <measurement group_id="O4" value="38.6" spread="24.46"/>
                    <measurement group_id="O5" value="70.0" spread="50.11"/>
                    <measurement group_id="O6" value="50.4" spread="36.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bladder Compliance at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated). Bladder Compliance was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bladder Compliance at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated). Bladder Compliance was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>milliliter per cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="2.828"/>
                    <measurement group_id="O2" value="6.97" spread="5.124"/>
                    <measurement group_id="O3" value="7.00" spread="2.828"/>
                    <measurement group_id="O4" value="8.16" spread="5.668"/>
                    <measurement group_id="O5" value="4.20" spread="2.307"/>
                    <measurement group_id="O6" value="6.98" spread="4.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="7.071"/>
                    <measurement group_id="O2" value="20.06" spread="46.151"/>
                    <measurement group_id="O3" value="9.00" spread="7.071"/>
                    <measurement group_id="O4" value="23.34" spread="55.493"/>
                    <measurement group_id="O5" value="12.40" spread="14.855"/>
                    <measurement group_id="O6" value="18.22" spread="42.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="6.152"/>
                    <measurement group_id="O2" value="13.22" spread="16.721"/>
                    <measurement group_id="O3" value="8.65" spread="6.152"/>
                    <measurement group_id="O4" value="13.18" spread="18.628"/>
                    <measurement group_id="O5" value="13.30" spread="15.836"/>
                    <measurement group_id="O6" value="12.39" spread="15.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="6.152"/>
                    <measurement group_id="O2" value="13.22" spread="16.721"/>
                    <measurement group_id="O3" value="8.65" spread="6.152"/>
                    <measurement group_id="O4" value="13.18" spread="18.628"/>
                    <measurement group_id="O5" value="13.30" spread="15.836"/>
                    <measurement group_id="O6" value="12.39" spread="15.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arms &quot;Cohort 1&quot;, &quot;Fesoterodine 8 mg Tablet&quot; and &quot;Fesoterodine 4 mg Capsule&quot; had &gt;0 micturitions at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arms &quot;Cohort 1&quot;, &quot;Fesoterodine 8 mg Tablet&quot; and &quot;Fesoterodine 4 mg Capsule&quot; had &gt;0 micturitions at baseline.</population>
          <units>micturitions per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.58" spread="4.541"/>
                    <measurement group_id="O4" value="4.58" spread="4.541"/>
                    <measurement group_id="O6" value="4.58" spread="4.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.50" spread="1.036"/>
                    <measurement group_id="O4" value="-1.50" spread="1.036"/>
                    <measurement group_id="O6" value="-1.50" spread="1.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.08" spread="0.631"/>
                    <measurement group_id="O4" value="-1.08" spread="0.631"/>
                    <measurement group_id="O6" value="-1.08" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.08" spread="0.631"/>
                    <measurement group_id="O4" value="-1.08" spread="0.631"/>
                    <measurement group_id="O6" value="-1.08" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>catheterizations per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="0.943"/>
                    <measurement group_id="O2" value="4.47" spread="1.390"/>
                    <measurement group_id="O3" value="5.33" spread="0.943"/>
                    <measurement group_id="O4" value="4.24" spread="1.641"/>
                    <measurement group_id="O5" value="5.00" spread="0.000"/>
                    <measurement group_id="O6" value="4.61" spread="1.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.471"/>
                    <measurement group_id="O2" value="0.05" spread="0.357"/>
                    <measurement group_id="O3" value="0.00" spread="0.471"/>
                    <measurement group_id="O4" value="0.03" spread="0.420"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="0.04" spread="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.000"/>
                    <measurement group_id="O2" value="-0.09" spread="0.278"/>
                    <measurement group_id="O3" value="0.33" spread="0.000"/>
                    <measurement group_id="O4" value="-0.19" spread="0.267"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="-0.02" spread="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.000"/>
                    <measurement group_id="O2" value="-0.12" spread="0.273"/>
                    <measurement group_id="O3" value="0.33" spread="0.000"/>
                    <measurement group_id="O4" value="-0.21" spread="0.249"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="-0.04" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions or Catheterizations Combined Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean number of micturitions and catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour (hr) period. This outcome measure was only calculated for participants with &gt;0 micturitions or catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions or Catheterizations Combined Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean number of micturitions and catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour (hr) period. This outcome measure was only calculated for participants with &gt;0 micturitions or catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>micturitions or catheterizations/24 hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="0.943"/>
                    <measurement group_id="O2" value="6.30" spread="2.808"/>
                    <measurement group_id="O3" value="5.33" spread="0.943"/>
                    <measurement group_id="O4" value="6.86" spread="3.259"/>
                    <measurement group_id="O5" value="5.00" spread="0.000"/>
                    <measurement group_id="O6" value="6.14" spread="2.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.471"/>
                    <measurement group_id="O2" value="-0.55" spread="1.131"/>
                    <measurement group_id="O3" value="0.00" spread="0.471"/>
                    <measurement group_id="O4" value="-0.83" spread="1.264"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="-0.46" spread="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.000"/>
                    <measurement group_id="O2" value="-0.57" spread="0.741"/>
                    <measurement group_id="O3" value="0.33" spread="0.000"/>
                    <measurement group_id="O4" value="-0.92" spread="0.665"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="-0.41" spread="0.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.000"/>
                    <measurement group_id="O2" value="-0.55" spread="0.703"/>
                    <measurement group_id="O3" value="0.33" spread="0.000"/>
                    <measurement group_id="O4" value="-0.83" spread="0.645"/>
                    <measurement group_id="O5" value="0.11" spread="0.192"/>
                    <measurement group_id="O6" value="-0.40" spread="0.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>incontinence episodes per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.236"/>
                    <measurement group_id="O2" value="3.60" spread="2.298"/>
                    <measurement group_id="O3" value="1.17" spread="0.236"/>
                    <measurement group_id="O4" value="3.48" spread="2.768"/>
                    <measurement group_id="O5" value="3.89" spread="0.770"/>
                    <measurement group_id="O6" value="3.19" spread="2.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.236"/>
                    <measurement group_id="O2" value="-0.18" spread="1.726"/>
                    <measurement group_id="O3" value="0.50" spread="0.236"/>
                    <measurement group_id="O4" value="-0.26" spread="2.074"/>
                    <measurement group_id="O5" value="0.00" spread="0.667"/>
                    <measurement group_id="O6" value="-0.07" spread="1.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.707"/>
                    <measurement group_id="O2" value="-0.31" spread="1.501"/>
                    <measurement group_id="O3" value="1.83" spread="0.707"/>
                    <measurement group_id="O4" value="-0.42" spread="1.577"/>
                    <measurement group_id="O5" value="-0.11" spread="1.644"/>
                    <measurement group_id="O6" value="0.08" spread="1.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.707"/>
                    <measurement group_id="O2" value="0.08" spread="1.894"/>
                    <measurement group_id="O3" value="1.83" spread="0.707"/>
                    <measurement group_id="O4" value="0.17" spread="2.110"/>
                    <measurement group_id="O5" value="-0.11" spread="1.644"/>
                    <measurement group_id="O6" value="0.38" spread="1.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for sensate participants with &gt;0 urgency episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No sensate participants for reporting arms &quot;Cohort 1&quot; and &quot;Fesoterodine 8 mg Tablet&quot; had &gt;0 urgency episodes at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for sensate participants with &gt;0 urgency episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No sensate participants for reporting arms &quot;Cohort 1&quot; and &quot;Fesoterodine 8 mg Tablet&quot; had &gt;0 urgency episodes at baseline.</population>
          <units>urgency episodes per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.61" spread="0.347"/>
                    <measurement group_id="O4" value="0.75" spread="0.354"/>
                    <measurement group_id="O5" value="0.33"/>
                    <measurement group_id="O6" value="0.61" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.61" spread="0.347"/>
                    <measurement group_id="O4" value="-0.75" spread="0.354"/>
                    <measurement group_id="O5" value="-0.33"/>
                    <measurement group_id="O6" value="-0.61" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.61" spread="0.347"/>
                    <measurement group_id="O4" value="-0.75" spread="0.354"/>
                    <measurement group_id="O5" value="-0.33"/>
                    <measurement group_id="O6" value="-0.61" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.61" spread="0.347"/>
                    <measurement group_id="O4" value="-0.75" spread="0.354"/>
                    <measurement group_id="O5" value="-0.33"/>
                    <measurement group_id="O6" value="-0.61" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Micturition at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per micturition. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arms &quot;Cohort 1&quot;, &quot;Fesoterodine 8 mg Tablet&quot; and &quot;Fesoterodine 4 mg Capsule&quot; had the records of volume voided per micturition.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Micturition at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per micturition. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS was analyzed. Here &quot;Overall Number of Participants Analyzed&quot;= participants evaluable for this outcome measure. No participant in reporting arms &quot;Cohort 1&quot;, &quot;Fesoterodine 8 mg Tablet&quot; and &quot;Fesoterodine 4 mg Capsule&quot; had the records of volume voided per micturition.</population>
          <units>milliliter per micturition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="73.42" spread="42.309"/>
                    <measurement group_id="O4" value="73.42" spread="42.309"/>
                    <measurement group_id="O6" value="73.42" spread="42.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="15.77" spread="6.924"/>
                    <measurement group_id="O4" value="15.77" spread="6.924"/>
                    <measurement group_id="O6" value="15.77" spread="6.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.75" spread="14.496"/>
                    <measurement group_id="O4" value="4.75" spread="14.496"/>
                    <measurement group_id="O6" value="4.75" spread="14.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.75" spread="14.496"/>
                    <measurement group_id="O4" value="4.75" spread="14.496"/>
                    <measurement group_id="O6" value="4.75" spread="14.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per catherization. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume &gt;0. This outcome measure included only participants who actually had the records of volume voided per catherization. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>milliliter per catheterization</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.75" spread="44.194"/>
                    <measurement group_id="O2" value="58.31" spread="40.187"/>
                    <measurement group_id="O3" value="198.75" spread="44.194"/>
                    <measurement group_id="O4" value="48.76" spread="39.230"/>
                    <measurement group_id="O5" value="80.58" spread="39.841"/>
                    <measurement group_id="O6" value="81.72" spread="66.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="21.095"/>
                    <measurement group_id="O2" value="20.66" spread="21.024"/>
                    <measurement group_id="O3" value="-0.92" spread="21.095"/>
                    <measurement group_id="O4" value="17.90" spread="17.038"/>
                    <measurement group_id="O5" value="27.08" spread="32.086"/>
                    <measurement group_id="O6" value="17.06" spread="21.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.42" spread="12.139"/>
                    <measurement group_id="O2" value="11.58" spread="27.064"/>
                    <measurement group_id="O3" value="-29.42" spread="12.139"/>
                    <measurement group_id="O4" value="8.72" spread="33.245"/>
                    <measurement group_id="O5" value="17.28" spread="9.659"/>
                    <measurement group_id="O6" value="4.12" spread="29.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.42" spread="12.139"/>
                    <measurement group_id="O2" value="11.58" spread="27.064"/>
                    <measurement group_id="O3" value="-29.42" spread="12.139"/>
                    <measurement group_id="O4" value="8.72" spread="33.245"/>
                    <measurement group_id="O5" value="17.28" spread="9.659"/>
                    <measurement group_id="O6" value="4.12" spread="29.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
        <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume &gt;0. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
        <time_frame>Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)</time_frame>
        <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg Tablet</title>
            <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Fesoterodine 2 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O5">
            <title>Fesoterodine 4 mg Capsule</title>
            <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
          </group>
          <group group_id="O6">
            <title>Total of Treatment Groups</title>
            <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109</title>
          <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume &gt;0. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.</description>
          <population>FAS included all participants who were enrolled and received at least one dose of study medication and had at least 1 observation in efficacy endpoint data after baseline visit in study A0221109. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>mL per micturition or catheterization</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.75" spread="44.194"/>
                    <measurement group_id="O2" value="65.68" spread="34.769"/>
                    <measurement group_id="O3" value="198.75" spread="44.194"/>
                    <measurement group_id="O4" value="59.29" spread="33.550"/>
                    <measurement group_id="O5" value="80.58" spread="39.841"/>
                    <measurement group_id="O6" value="87.86" spread="62.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="21.095"/>
                    <measurement group_id="O2" value="17.88" spread="17.597"/>
                    <measurement group_id="O3" value="-0.92" spread="21.095"/>
                    <measurement group_id="O4" value="13.94" spread="7.801"/>
                    <measurement group_id="O5" value="27.08" spread="32.086"/>
                    <measurement group_id="O6" value="14.75" spread="18.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.42" spread="12.139"/>
                    <measurement group_id="O2" value="12.34" spread="26.812"/>
                    <measurement group_id="O3" value="-29.42" spread="12.139"/>
                    <measurement group_id="O4" value="9.86" spread="33.029"/>
                    <measurement group_id="O5" value="17.28" spread="9.659"/>
                    <measurement group_id="O6" value="4.75" spread="29.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.42" spread="12.139"/>
                    <measurement group_id="O2" value="12.34" spread="26.812"/>
                    <measurement group_id="O3" value="-29.42" spread="12.139"/>
                    <measurement group_id="O4" value="9.86" spread="33.029"/>
                    <measurement group_id="O5" value="17.28" spread="9.659"/>
                    <measurement group_id="O6" value="4.75" spread="29.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)</time_frame>
      <desc>Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study. Safety analysis population evaluated. AEs were summarized for each cohort (Cohort 1 and Cohort 2), each treatment group and the total of treatment groups , using the merged data of studies A0221047 and A0221109 as planned.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Participants of cohort 1 with body weight &gt;25 kg, who received fesoterodine 4 mg or 8 mg PR tablet orally once daily for 24 weeks (active comparator and safety extension phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Participants of cohort 2 with body weight &lt;=25 kg, who received either fesoterodine 2 mg or 4 mg capsule orally once daily for 24 weeks (efficacy and safety phase) in precedent study A0221047 and then continued the same dose and dosage form of fesoterodine for 28 weeks in this LTE study.</description>
        </group>
        <group group_id="E3">
          <title>Fesoterodine 8 mg Tablet</title>
          <description>Participants of cohort 1, with body weight &gt;25 kg, who received fesoterodine 4 mg PR tablet for 1 week and if tolerated well then fesoterodine 8 mg PR tablet once daily for 11 weeks in active comparator and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 8 mg PR tablet orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="E4">
          <title>Fesoterodine 2 mg Capsule</title>
          <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 24 weeks (12 weeks in each efficacy and safety extension phase) in precedent study and who continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="E5">
          <title>Fesoterodine 4 mg Capsule</title>
          <description>Participants of cohort 2, with body weight &lt;=25 kg, received fesoterodine 2 mg BIC capsules orally once daily for 1 week and if well tolerated then fesoterodine 4 mg BIC capsules orally once daily for 11 weeks in efficacy phase and 12 weeks in safety extension phase in precedent study A0221047 and who continued to receive fesoterodine 4 mg BIC capsules orally once daily for another 28 weeks in this LTE study.</description>
        </group>
        <group group_id="E6">
          <title>Total of Treatment Groups</title>
          <description>Total participants who received fesoterodine 8 mg PR tablet, fesoterodine 2 mg and 4 mg BIC capsules in precedent study A0221047 and continued to receive the same treatment respectively, in this LTE study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urodynamics measurement abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Prioritization of outcome measures was based on study team's discretion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

